DEA Revokes Arizona Nurse's License Over Drug Violations
Published Date: 4/22/2025
Notice
Summary
Svetlana Burtman, a nurse practitioner in Arizona, had her DEA registration suspended and is facing revocation because she broke important rules about handling controlled substances. The government found she gave out drugs from an unregistered location and didn’t keep proper records, which could risk public safety. This decision means she can’t legally dispense these drugs anymore, and her new clinic’s registration was also denied.
Analyzed Economic Effects
5 provisions identified: 0 benefits, 5 costs, 0 mixed.
DEA Registration Revoked for Practitioner
The Drug Enforcement Administration agreed to revoke Svetlana Burtman’s DEA Certificate of Registration No. MB2645767 and suspended that registration after an Order to Show Cause on December 28, 2023. The Decision and Order (published April 22, 2025) means she can no longer legally dispense or administer controlled substances under that registration.
New Clinic Registration Denied
The DEA denied Respondent’s application for a separate registration for her Green Valley Clinic (application No. W23106194M), and the Agency found she dispensed controlled substances at that unregistered location. The Agency’s findings note she dispensed at Green Valley after July 19, 2023 and that the GVC application was not approved.
Separate Registration Required per Location
The Agency reaffirmed that each principal place of business where controlled substances are dispensed requires a separate DEA registration under 21 CFR 1301.12(a). The Decision points to the Green Valley Clinic as an unregistered location where dispensing occurred, citing dispensing logs and admissions.
Strict Recordkeeping and Dispensing Log Rules Enforced
The Agency found Respondent failed to maintain complete, readily retrievable records of controlled substances received (citing 21 U.S.C. 827 and 21 CFR 1304.04/1304.21) and failed to keep required dispensing logs (21 CFR 1304.22(c)). The missing Tucson purchase invoice records and incomplete dispensing logs were relied on in the Agency’s decision.
Must Accept Responsibility to Retain Registration
The Decision reiterates that a registrant seeking to retain or regain a DEA registration must unequivocally accept responsibility for misconduct and demonstrate they will not reoffend. The Agency found Respondent minimized her unlawful conduct and did not meet that standard.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20226, By Grace Inc. Counseling Services; Decision and Order
By Grace Inc. Counseling Services in Baltimore faced losing its DEA license because it didn’t keep good records and lied about its owner’s past drug conviction. After a hearing, the DEA decided to revoke their registration, meaning they can’t legally handle controlled substances anymore. This affects the clinic’s ability to operate and could impact patients relying on their services.
2026-20227, St. Michael's Pharmacy; Decision and Order
St. Michael's Pharmacy in Texas had its DEA license suspended and is facing revocation because it kept filling risky drug prescriptions without fixing obvious warning signs of abuse. This affects the pharmacy’s ability to legally handle controlled substances and could impact patients relying on it. The pharmacy must now deal with these serious legal actions, which started in late 2025 and could lead to permanent closure or fines.
Previous / Next Documents
Previous: 2025-06879, National Center for Advancing Translational Sciences; Notice of Closed Meeting
The National Center for Advancing Translational Sciences is holding a private meeting on May 14-15, 2025, to review secret contract proposals about developing new drug products. This meeting affects companies and researchers involved in drug development and keeps sensitive info safe. No public money changes are announced, but the decisions could impact future drug research funding.
Next: 2025-06883, Information Collection Being Reviewed by the Federal Communications Commission Under Delegated Authority
The FCC is asking the public and other agencies to help review and improve how it collects information, aiming to cut down on paperwork and make things easier for everyone—especially small businesses. They want to know if the info they ask for is really needed, clear, and not too much of a hassle. This is a chance to share ideas before any changes happen, so keep an eye out and speak up!